Active Ingredient History
Rivastigmine (sold under the trade name Exelon) is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease. Rivastigmine, an acetylcholinesterase inhibitor, inhibits both butyrylcholinesterase and acetylcholinesterase (unlike donepezil, which selectively inhibits acetylcholinesterase). It is thought to work by inhibiting these cholinesterase enzymes, which would otherwise break down the brain neurotransmitter acetylcholine. Rivastigmine capsules, liquid solution, and patches are used for the treatment of mild to moderate dementia of the Alzheimer's type and for mild to moderate dementia related to Parkinson's disease. Rivastigmine has demonstrated treatment effects on the cognitive (thinking and memory), functional (activities of daily living) and behavioral problems commonly associated with Alzheimer's and Parkinson's disease dementia. In people with either type of dementia, rivastigmine has been shown to provide meaningful symptomatic effects that may allow patients to remain independent and ‘be themselves’ for longer. In particular, it appears to show marked treatment effects in patients showing a more aggressive course of the disease, such as those with younger-onset ages, poor nutritional status, or those experiencing symptoms such as delusions or hallucinations. Side effects may include nausea and vomiting, decreased appetite and weight loss. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alzheimer Disease (Phase 4)
Anxiety Disorders (Phase 3)
Apathy (Phase 3)
Biological Availability (Early Phase 1)
Brain Injuries, Traumatic (Phase 4)
Central Nervous System Diseases (Phase 1)
Cholinesterase Inhibitors (Phase 4)
Cocaine-Related Disorders (Phase 1)
Cognition Disorders (Phase 4)
Cognitive Dysfunction (Phase 4)
Delirium (Phase 4)
Dementia (Phase 3)
Dementia, Vascular (Phase 3)
Depression (Phase 3)
Depressive Disorder (Phase 4)
Down Syndrome (Phase 1/Phase 2)
Healthy Volunteers (Phase 4)
HIV Infections (Phase 4)
Hypotension, Orthostatic (Phase 1)
Methamphetamine (Phase 1)
Multiple Sclerosis (Phase 4)
Neurobehavioral Manifestations (Phase 3)
Parkinson Disease (Phase 4)
Postoperative Cognitive Complications (Phase 4)
Psychophysiologic Disorders (Phase 3)
Pure Autonomic Failure (Phase 1)
Schizophrenia (Phase 3)
Stroke (Phase 4)
Substance-Related Disorders (Phase 1)
Supranuclear Palsy, Progressive (Phase 3)
Therapeutic Equivalency (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
